Citadel Advisors
HPTX

Citadel Advisors’s HYPERION THERAPEUTICS INC COM STK (DE) HPTX Stock Holding History

Citadel Advisors’s Portfolio HPTX Stock Details HPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-5,215
Closed -$239K – 9457
2015
Q1 		$239K Sell
5,215
-72,101
-93% -$2.16M ﹤0.01% 5961
2014
Q4 		$1.86M Buy
77,316
+328
+0.4% +$7.39K ﹤0.01% 2997
2014
Q3 		$1.94M Buy
76,988
+46,367
+151% +$1.15M ﹤0.01% 2874
2014
Q2 		$799K Buy
30,621
+11,110
+57% +$286K ﹤0.01% 3786
2014
Q1 		$503K Sell
19,511
-6,890
-26% -$187K ﹤0.01% 4339
2013
Q4 		$534K Buy
+26,401
New +$621K ﹤0.01% 3947

Citadel Advisors's HPTX Position: Q2 2015 in Review

Citadel Advisors sold out of HYPERION THERAPEUTICS INC COM STK (DE) (HPTX) in Q2 2015, closing a stake of 5,215 shares — an estimated $239K sold.

Citadel Advisors first reported a position in HPTX in Q4 2013 and held it in 6 quarters. The position peaked at $1.94M in Q3 2014. 0 funds tracked by Wall St. Rank hold HPTX as of Q2 2015.

  • Citadel Advisors reported no remaining HYPERION THERAPEUTICS INC COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Citadel Advisors sold 5,215 HYPERION THERAPEUTICS INC COM STK (DE) shares in Q2 2015, an estimated $239K.
  • Citadel Advisors first reported a position in HYPERION THERAPEUTICS INC COM STK (DE) in Q4 2013 and held it in 6 quarters.
  • Citadel Advisors's HYPERION THERAPEUTICS INC COM STK (DE) position peaked at $1.94M in Q3 2014.
  • 0 funds tracked by Wall St. Rank held HYPERION THERAPEUTICS INC COM STK (DE) as of Q2 2015.

Based on Citadel Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.